Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

335.16USD
20 Feb 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$335.16
Open
$332.37
Day's High
$335.30
Day's Low
$331.90
Volume
342,661
Avg. Vol
524,983
52-wk High
$388.67
52-wk Low
$249.24

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $69,239.67
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 21.50 30.48 33.70
EPS (TTM): 15.23 -- --
ROI: 17.59 14.95 14.45
ROE: 28.64 16.27 15.96

Biogen beats estimates on multiple sclerosis drugs sales

Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, buoyed by higher sales of its top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.

29 Jan 2019

UPDATE 2-Biogen beats estimates on multiple sclerosis drugs sales

Jan 29 Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, buoyed by higher sales of its top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.

29 Jan 2019

CORRECTED-UPDATE 1-Biogen beats estimates on Spinraza, Tecfidera strength

Jan 29 Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, driven by demand for its muscle disease treatment Spinraza and top-selling multiple sclerosis drug Tecfidera.

29 Jan 2019

Drugmaker Biogen's fourth-quarter revenue rises 6.6 pct

Jan 29 Biogen Inc reported a 6.6 percent rise in fourth-quarter revenue on Tuesday, driven by higher sales of its blockbuster muscle disease treatment Spinraza.

29 Jan 2019

Ireland demands $1.9 billion in back taxes from Perrigo

DUBLIN Ireland's tax authorities have demanded that drugmaker Perrigo , formerly known as Elan, pay 1.64 billion euros ($1.9 billion) in taxes relating to the calendar year 2013, a U.S. securities filing showed.

21 Dec 2018

Ireland demands $1.9 billion in back taxes from Perrigo

DUBLIN Ireland's tax authorities have demanded that drugmaker Perrigo , formerly known as Elan, pay 1.64 billion euros (1.48 billion pounds) in taxes relating to the calendar year 2013, a U.S. securities filing showed.

21 Dec 2018

Ireland demands $1.9 bln in back taxes from Perrigo

DUBLIN, Dec 21 Ireland's tax authorities have demanded that drugmaker Perrigo, formerly known as Elan, pay 1.64 billion euros ($1.9 billion) in taxes relating to the calendar year 2013, a U.S. securities filing showed.

21 Dec 2018

Swiss stocks - Factors to watch on Dec. 21

ZURICH/BERLIN, Dec 21 The Swiss blue-chip SMI, which is down 10.3 percent on the year, was seen opening 0.1 percent lower at 8,404 points on Friday, according to premarket indications by bank Julius Baer.

21 Dec 2018

U.S. body says gene therapy may be more cost effective for spinal muscular atrophy

NEW YORK/ZURICH Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.

21 Dec 2018

UPDATE 1-U.S body says gene therapy may be more cost effective for spinal muscular atrophy

NEW YORK/ZURICH, Dec 20 Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.

21 Dec 2018

Earnings vs. Estimates